Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Counsyl | RCV000672949 | SCV000798108 | likely pathogenic | Peroxisome biogenesis disorder type 3B; Peroxisome biogenesis disorder 3A (Zellweger) | 2018-02-26 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV003653257 | SCV004374558 | pathogenic | Peroxisome biogenesis disorder 3A (Zellweger) | 2023-05-08 | criteria provided, single submitter | clinical testing | ClinVar contains an entry for this variant (Variation ID: 556886). For these reasons, this variant has been classified as Pathogenic. This variant disrupts a region of the PEX12 protein in which other variant(s) (p.Gln349del) have been determined to be pathogenic (PMID: 15542397, 21031596; Invitae). This suggests that this is a clinically significant region of the protein, and that variants that disrupt it are likely to be disease-causing. This variant has not been reported in the literature in individuals affected with PEX12-related conditions. This variant is present in population databases (no rsID available, gnomAD 0.1%). This sequence change creates a premature translational stop signal (p.Pro215Glnfs*6) in the PEX12 gene. While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 145 amino acid(s) of the PEX12 protein. |